Article
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
Clinical pharmacology and therapeutics - 1 Oct 2011
Johnson J A, Gong L, Whirl-Carrillo M, Gage B F, Scott S A, Stein C M, Anderson J L, Kimmel S E, Lee M T M, Pirmohamed M, Wadelius M, Klein T E, Altman R B
Abstract excerpt
Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to known nongenetic factors, account for ~50% of warfarin dose variability. The purpose of this article is to assist in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.